Les Meilleurs doctors pour le traitement de myélome en Israël - TOP-18 des médecins

Le professeur Ron Ram exerce au centre médical Sourasky (Ichilov), le plus grand hôpital universitaire d'Israël.

• Son collègue, le professeur Fredi Aviv, y dirige l'unité de greffe de moelle osseuse
• L'équipe se spécialise dans les cancers hématologiques, y compris le myélome
• Utiliser des traitements avancés comme l'immunothérapie cellulaire
• Le centre est à la pointe de la recherche sur la greffe de cellules souches autologues

Le Dr Ron Ram a réalisé plusieurs centaines de greffes de cellules souches au centre médical Sourasky – une procédure clé pour le traitement du myélome.

• Certifié en médecine interne, en hématologie et en oncologie médicale
• Publier plus de 30 articles scientifiques et un chapitre de manuel sur l'hématologie
• Effectuer son spécialisation en hématologie et oncologie au New York Medical College
• Offrir une approche individualisée pour chaque patient transplanté

Le Dr El Hasid a réalisé plus de 300 greffes de moelle osseuse et de sang de cordon chez l'enfant. Elle dirige le service d'onco-hématologie et d'oncologie pédiatrique de l'hôpital pour enfants Dana Dwek.

• Se spécialiser dans la greffe de moelle osseuse et de sang ombilical pédiatrique
• Être membre de l'Association américaine d'hématologie
• Être membre de la Société israélienne d'hémato-oncologie pédiatrique
• Suivre une formation au célèbre City of Hope Hospital de Los Angeles
• Rédiger 50 publications et 40 rapports de conférence

Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.

He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.

He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.

His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.

Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.

She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.

She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.

She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.

Le Dr Michael Shapira est un hématologue de renommée, connu pour avoir prouvé que l'âge n'est pas un obstacle à la réussite des greffes de cellules souches. Il dirige l'unité d'hospitalisation et l'hôpital de jour d'hématologie au centre médical Tel Aviv Sourasky.

• Se spécialiser dans la greffe de moelle osseuse pour les patients âgés
• Traiter la maladie du greffon contre l'hôte (GVHD)
• Anciennement médecin principal au département de greffe de cellules souches de l'hôpital Hadassah Ein Kerem
• Être membre de plusieurs associations médicales internationales
• Être diplômé de la faculté de médecine de l'Université hébraïque de Jérusalem

Le Dr Fredi Aviv se consacre au myélome depuis 31 ans au centre médical Sourasky, le principal hôpital de Tel Aviv.

• Se spécialiser en tant qu'onco-hématologue, traitant spécifiquement les cancers du sang
• Posséder une vaste expérience dans la gestion de protocoles complexes de traitement des cancers du sang
• Travailler au sein de l'un des centres médicaux les plus importants et les plus complets d'Israël

Le Dr Dror Levin est un expert de premier plan en matière de troubles sanguins pédiatriques et de cancer des os, dirigeant le département d'hémato-oncologie pédiatrique du centre médical Sourasky.

• Se spécialiser dans le traitement du cancer des os (sarcome) chez les enfants
• Membre de l'association israélienne d'hémato-oncologie pédiatrique (ISPHO)
• Se former à l'Institut orthopédique Rizzoli en Italie – un leader mondial en oncologie osseuse
• Coordonner le traitement des troubles de la coagulation sanguine chez les enfants

Le Dr Kirshner participe activement à la recherche sur le myélome et aux essais cliniques, notamment aux essais de phase III testant de nouvelles combinaisons de traitements.

• Formation spécialisée (Fellowship) en hématologie et oncologie médicale au Montefiore Medical Center
• Se spécialiser dans les approches de traitement avancées pour le myélome
• Longue expérience de travail au prestigieux centre médical Sourasky
• Certification en médecine interne et en oncologie

Le Dr Yair est un hématologue primé au Sourasky Medical Center, spécialisé dans les cancers du sang tels que le myélome.

• Plusieurs bourses de recherche et prix pour ses contributions à l'hématologie
• Membre des associations israélienne et américaine d'hématologie
• Formation approfondie en hématologie au centre médical de Tel Aviv

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Le professeur Ben-Yehuda est chef du service d'hématologie du centre médical Hadassah et doyenne reconnue de sa faculté de médecine.

• Plus de 30 ans d'expérience dans le traitement des maladies malignes du sang, y compris le myélome
• Formation au prestigieux Memorial Sloan-Kettering Cancer Center à New York
• Spécialisation dans la greffe de moelle osseuse et la thérapie génique avancée
• Direction de recherches en diagnostic moléculaire pour les maladies hématologiques
• Titulaire du prix « Healing with the Heart » pour l'excellence des soins aux patients

L'onco-hématologue Ofer Spielberg traite les cancers du sang au centre médical Assuta.

• Se spécialiser exclusivement dans le traitement du myélome et d'autres troubles sanguins
• Travailler au sein d'un important réseau hospitalier israélien reconnu pour son oncologie de pointe

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.